Navigation Links
Lifeline Biotechnologies Receives Third Software Patent
Date:9/17/2012

RENO, Nev., Sept. 17, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (OTC Market: LLBO) announces the award of US Patent #8,231,542 B2 for System For Analyzing Thermal Data Based on Breast Surface Temperature to  Determine Suspect Conditions.

Jim Holmes, Lifeline's CEO said, "This System patent completes our group of three software patents.  We now have our Methods, Device and System patents which provide the Company with protection of its developed technology.  Methods for Collecting and Analyzing Thermal Data Based on Breast Surface Temperature to Determine Suspect Conditions;   Device For Analyzing Thermal Data Based On Breast Surface Temperature For Detection For Use In Determining Cancerous Conditions;  and, System For Analyzing Thermal Data Based On Breast Surface Temperature To Determine Suspect Conditions."

First Warning Systems, Lifeline Biotechnologies' exclusive licensee, is currently updating the patient data collection device and its interpretive software, covered by these patents, to complete the product package in preparation for market entry.  First Warning is conducting a funding round.  Company information is being posted on GUST (an association of angel investors who are accredited and qualified).

About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV.  FWS' principal shareholder is Lifeline Biotechnologies, Inc.  Lifeline has licensed (includes a revenue royalty feature) FWS with the worldwide exclusive right for  development, manufacturing, marketing and commercialization of its intellectual property.  The product  is a device and process that detects breast tissue abnormalities.  Many of these tissue abnormalities will develop into breast diseases, some of which will be breast cancers.  The FWS process does not involve compression or radiation and is noninvasive. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other protocols.  FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russian markets. See FWS' video, "Breast Cancer Tumor Progression" at www.firstwarningsystems.com.

About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV.  LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer.  Three "Proof of Concept" clinical trials of over 650 women have been completed and four patents (one hardware, three software) have been awarded. www.lbti.com. Lifeline's efforts continue to have DTC remove the chill and allow trading to resume.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

For more information, contact:   Jim Holmes, CEO 775-852-3222     Email: Jholmes@lbti.com           


'/>"/>
SOURCE Lifeline Biotechnologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lifeline Biotechnologies First Warning Systems
2. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
3. Dehaier Medical Receives SFDA Approval for DHR-CPAP-C5
4. TechPrecision Receives Additional Medical Purchase Orders Exceeding $1.5 Million
5. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
6. NeuroSigma Receives CE Certification
7. Surefire Medicals Infusion System For Embolization Procedures Receives CE Mark Approval
8. Roche receives FDA clearance for herpes simplex virus type 1 and 2 tests
9. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
10. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. China Botanic Receives New Patent on its Comprehensive Method to Enhance the Medicinal Value of Schisandra
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... and EDMONTON, Alberta ... ) scientists and the University of Alberta in ... new data in Nature,s partner journal, Schizophrenia 1 ... helped predict instances of schizophrenia with 74% accuracy. ... the severity of specific symptoms in schizophrenia patients ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... “Journey to the Light: The Quest for Happiness ... young woman’s path to finding herself. “Journey to the Light: The Quest for ... Grayson, an experienced writer of newsletters, manuals, and articles, who has recently decided to ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... of education and training standards for healthcare treatment providers, offers healthcare professionals ... the iaedp™ Core Curriculum. , Presented as either online or as a ...
(Date:7/23/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 23, ... ... the effects of single sport specialization is critical, say researchers presenting their work ... Meeting in Toronto, Canada. , “Our study is the first one to ...
(Date:7/23/2017)... ... 23, 2017 , ... “I Am Not Nothin’: The Serpent Handler’s Daughter” is ... read and write and a brokenhearted young soldier who turned to whiskey after his ... about the power of simple faith is the work of published author Tommy G. ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a leading ... Patent No. 9,038,640 by the United States Patent and Trademark Office. The patent ... of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and safety ...
Breaking Medicine News(10 mins):